Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the…
Month: March 2025
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to…
Unexpected Benefit: Popular Weight Loss Drug Ozempic Could Also Help You Drink Less – SciTechDaily
Unexpected Benefit: Popular Weight Loss Drug Ozempic Could Also Help You Drink Less SciTechDaily
These discounted versions of popular weight-loss drugs are going away: What to know – USA TODAY
These discounted versions of popular weight-loss drugs are going away: What to know USA TODAY
What’s Next for Semaglutide? Beyond Diabetes and Weight Loss – News-Medical.Net
What's Next for Semaglutide? Beyond Diabetes and Weight Loss News-Medical.Net
The weight-loss drugs being tested in 2025: will they beat Ozempic? – Nature.com
The weight-loss drugs being tested in 2025: will they beat Ozempic? Nature.com
Weight loss drugs may become harder to get. What does that mean for patients? – WBUR News
Weight loss drugs may become harder to get. What does that mean for patients? WBUR News
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about unintended effects – LINK nky
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about unintended effects LINK nky
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The CHMP has recommended the approval of AbbVie’s upadacitinib (Rinvoq) for treating adults with giant cell…
Rare disease treatments skipping UK patients largely due to costs, survey shows
A survey has shown that pharma companies have low confidence their rare disease medicines can launch…